Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-07

Clinical Trial Update: Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) [Phase 3]

View source ↗

Summary

A Phase 3 feasibility study evaluating PH94B nasal spray for acute treatment of social anxiety disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PH94B Nasal Spray (PH94B)

Snippet

Sponsor: Pherin Pharmaceuticals, Inc. | Conditions: Social Anxiety Disorder | Phase 3 | Status: COMPLETED